Concepedia

Author

Vladimir Cmiljanović

PIQUR Therapeutics (Switzerland)

Also Known As

Cmiljanović, Vladimir, V. Cmiljanovic, Vladimir Cmiljanovic, Vladimir Cmiljanović

57

Publications

1.2K

Citations

9

H-Index

16

Concepts

All Affiliations

PIQUR Therapeutics (Switzerland)University of BaselMRC Laboratory of Molecular BiologyUniversity College London Hospitals NHS Foundation TrustUniversity Hospital of Basel
VC

About

Vladimir Cmiljanović is an author at PIQUR Therapeutics (Switzerland) specializing in pharmacotherapy, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

194

2

Pharmacology

2

2

194

3

Immunology

1

1

132

4

Cancer Therapeutics

1

1

62

5

Drug Development

1

1

132

Vladimir Cmiljanović

×

8

Publications

592

Citations

8

H-Index

YearCitations

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović,

Journal of Medicinal Chemistry

2017

132

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

Romina Marone, Dominik Erhart, Ann C. Mertz,

Molecular Cancer Research

2009

124

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

Chiara Tarantelli, Eugenio Gaudio, Alberto J. Arribas,

Clinical Cancer Research

2017

117

Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

Thomas Bohnacker, A.E. Prota, Florent Beaufils,

Nature Communications

2017

113

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Andreas Wicki, Nicholas F. Brown, Alexandros Xyrafas,

European Journal of Cancer

2018

62

A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications

Jacob Schön, G. Tuba Barut, Bettina Salome Trüeb,

Nature Microbiology

2024

17

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

Chiara Tarantelli, Eugenio Gaudio, Petra Hillmann,

Cancers

2019

16

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

Filip Jankú, Grace M. Choong, Mateusz Opyrchal,

Cancers

2024

11

Page 1